“Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD”. SKIN The Journal of Cutaneous Medicine, vol. 10, no. 2, Mar. 2026, p. s731, https://doi.org/10.25251/26swpe94.